Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease.
Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease.
复制标题
DOI：
10.3389/fmed.2023.1137981
复制
发表时间：
2023
影响因子：
3.9
通讯作者：
中科院分区：
文献类型：
--
作者：
高钾血症是慢性肾脏病（CKD）患者中公认的电解质异常。钾结合剂通常用于预防和治疗高钾血症。然而，很少有研究评估新型钾结合剂环硅酸锆钠 (ZSC) 与传统药物在急性期后血清钾 (K+) 水平降低作用的差异。这项回顾性研究纳入了2020年5月至2022年7月期间在我院接受钾结合剂（ZSC或聚苯乙烯磺酸钙[CPS]）治疗的患者。患者分为ZSC组和CPS组。倾向评分匹配后，我们比较了两组之间电解质（包括 K+ 水平）从基线到第一个随访点（在开始钾结合剂至少 4 周后）的变化。在 132 名患者中，分别有 48 名和 84 名患者接受了 ZSC 和 CPS。匹配后，每组各有38名患者。 ZSC 组的 K+ 水平比 CPS 组显着降低（P < 0.05）。此外，在 ZSC 组中观察到血清钠减去氯化物水平（代谢性酸中毒的替代标志物）显着增加（P < 0.05）。我们的结果表明，ZSC 可能会改善 CKD 患者的高钾血症和代谢性酸中毒。
Hyperkalemia is a well-recognized electrolyte abnormality in patients with chronic kidney disease (CKD). Potassium binders are often used to prevent and treat hyperkalemia. However, few studies have evaluated the difference in serum potassium (K+) level-lowering effect during the post-acute phase between the novel potassium binder, sodium zirconium cyclosilicate (ZSC), and conventional agents. This retrospective study included patients who received potassium binders (either ZSC or calcium polystyrene sulfonate [CPS]) in our hospital between May 2020 and July 2022. The patients were divided into the ZSC and CPS groups. After propensity score matching, we compared changes from baseline to the first follow-up point, at least 4 weeks after initiating potassium binders, in electrolytes including K+ level between the two groups. Of the 132 patients, ZSC and CPS were administered in 48 and 84 patients, respectively. After matching, 38 patients were allocated to each group. The ZSC group showed greater reduction in K+ levels than did the CPS group (P < 0.05). Moreover, a significant increase in serum sodium minus chloride levels, a surrogate marker for metabolic acidosis, was observed in the ZSC group (P < 0.05). Our results demonstrated that ZSC could potentially improve hyperkalemia and metabolic acidosis in patients with CKD.
影响因子：
4.6
作者：
通讯作者：
--